---
title: "Encoded Therapeutics Raises $275M Series F to Take Its Dravet Gene Therapy Through Pivotal Development"
description: "GV and an unnamed healthcare fund co-led Encoded Therapeutics' $275 million Series F, financing pivotal ETX101 studies, internal GMP scale-up, and a 2027 IND target for ETX301."
date: 2026-09-09T00:00:00.000Z
source: https://venturecapitaltracker.com/2026-encoded-therapeutics-275m-series-f-dravet
---

# Encoded Therapeutics Raises $275M Series F to Take Its Dravet Gene Therapy Through Pivotal Development

> GV and an unnamed healthcare fund co-led Encoded Therapeutics' $275 million Series F, financing pivotal ETX101 studies, internal GMP scale-up, and a 2027 IND target for ETX301.

**Encoded Therapeutics** closed a **$275 million Series F** on **September 9, 2026**. **GV** and an unnamed healthcare fund co-led, with **ARCH Venture Partners, Braidwell, Farallon, Illumina Ventures, Invus, Janus Henderson, Matrix Capital, Nolan Capital, RTW Investments, SoftBank Vision Fund 2**, and **Venrock** participating.

the financing is a late-stage clinical and manufacturing bet. It is intended to carry lead program **ETX101** through pivotal development while scaling internal GMP capacity rather than outsourcing the entire production path.

## Key facts

| Field | Detail |
| --- | --- |
| Company | [Encoded Therapeutics](/startup/encoded-therapeutics) |
| Financing | **$275M Series F**, closed |
| Co-leads | GV; one unnamed healthcare fund |
| Lead program | ETX101 for **SCN1A+ Dravet syndrome** |
| Development | Pivotal study in infants and young children; expansion study through age 18 |
| Pipeline | ETX301 targeting a **2027 IND** submission for post-amputation neuroma pain |
| Manufacturing | Commercial scale-up of internal GMP capabilities |

## What the round must prove

Encoded describes ETX101 as a one-time precision genetic medicine. The company cited interim Phase 1/2 POLARIS data showing seizure-frequency reductions and developmental gains, but the financing thesis now shifts from early signal to pivotal evidence, registration readiness, and reproducible manufacturing.

The internal GMP expansion may create more control over quality and timelines. It also increases fixed-cost and execution exposure before approval.

## Why an anonymous co-lead matters

The company disclosed GV but not the second healthcare fund. That anonymity should be preserved: it is not evidence that any other participant co-led. The broad syndicate supplies biotechnology, crossover, and growth capital, but Encoded did not disclose valuation, ownership, or round structure.

## What remains undisclosed

- Valuation and primary/secondary mix
- The identity of the second co-lead
- Trial enrollment, pivotal timelines, and regulatory milestones beyond the stated programs
- Expected cost and capacity of the GMP expansion

## Takeaway

The **$275 million** is large because Encoded is financing three linked risks at once: a pivotal study, commercial manufacturing preparation, and a follow-on neurology pipeline. The next valuation-relevant evidence will be clinical durability and the ability to manufacture consistently—not the size of this syndicate.

Day index: [September 11–12 investment news](/2026-september-11-12-investment-news-chips-biotech-fintech).

### Source

1. [Encoded Therapeutics — Series F announcement](https://encoded.com/encoded-therapeutics-raises-275-million-in-series-f-financing-to-advance-etx101-through-pivotal-development-and-accelerate-its-precision-genetic-medicines-neurology-pipeline/)

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.